Stevens Kathryn K, Patel Rajan K, Jardine Alan G
Renal Research Group, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, UK.
J Ren Care. 2012 Feb;38 Suppl 1:125-37. doi: 10.1111/j.1755-6686.2012.00282.x.
New-onset diabetes after transplantation (NODAT) has serious consequences for the patient in terms of overall survival, graft function and graft survival. The incidence of NODAT and impaired glucose tolerance has probably been underestimated previously because of lack of a universal diagnostic definition. Many risk factors have been identified, a proportion of which are modifiable. Early identification of those who are at high risk of NODAT and strategies to reduce risk will help to reduce the morbidity and mortality resulting from this condition. Where prevention is not possible, stringent management strategies are essential. Although, this article focuses on NODAT in the renal transplant recipient and considers the scale of the problem, impact on patient and transplant survival, determinants and risk factors for, and the management of, impaired glucose tolerance and NODAT, much of it will also be applicable to other types of solid organ transplantation.
移植后新发糖尿病（NODAT）在患者的总体生存、移植物功能和移植物存活方面具有严重后果。由于缺乏通用的诊断定义，NODAT和糖耐量受损的发生率此前可能被低估了。已确定许多风险因素，其中一部分是可改变的。早期识别NODAT高危人群并采取降低风险的策略，将有助于降低由此导致的发病率和死亡率。在无法预防的情况下，严格的管理策略至关重要。尽管本文重点关注肾移植受者中的NODAT，并探讨了该问题的规模、对患者和移植存活的影响、糖耐量受损和NODAT的决定因素及风险因素以及管理方法，但其中许多内容也适用于其他类型的实体器官移植。
